PharmVar Launches Website
The Cytochrome P450 (CYP) Allele Nomenclature Database has transitioned to the Pharmacogene Variation Consortium at www.PharmVar.org. Please check out the PharmVar website!
More issues
Welcome to the new PharmGKB website!
We have just launched our new and improved user interface for PharmGKB!
The new website offers benefits such as a display that works on mobile and small screen devices, improved searching and filtering capabilities and faster page load speeds. While the look of PharmGKB has changed, all the content that
Announcing PharmVar
PharmVar will be taking over the allele designations for the cytochrome P450 genes from the Human Cytochrome P450 (CYP) Allele Nomenclature Database, and later expanding to become a central repository for other pharmacogenes as well. PharmGKB will partner with PharmVar to make sure PharmGKB has the most up-to-date pharmacogene allele
Pharmacogenetics/Genomics (PGx) and Depression Featured on NBC News
On August 7th, NBC News aired a segment on how pharmacogenomics can help treat patients with depression. It highlighted the story of Sarah Ellis from Sioux Falls, SD who had trouble finding a combination of antidepressant and anti-anxiety medications that did not induce debilitating adverse effects. She had tried 23
Curators' Favorite Papers
Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)Just KS, Steffens M, Swen JJ, Patrinos GP, Guchelaar HJ, Stingl JC.Ubiquitous Pharmacogenetics (U-PGx) is a pharmacogenetics implementation project across multiple sites, in countries across
The Roles of CYP2C19 and CYP3A4 in Voriconazole Pharmacogenetics
Voriconazole is a triazole antifungal agent used to treat serious fungal infections. It is primarily used in immunocompromised patients, such as those undergoing organ transplantation. CYP2C19 is the primary enzyme responsible for voriconazole metabolism. CYP3A4, CYP3A5 and CYP2C9 also play a role, secondary to CYP2C19. The influence of genetic polymorphisms
Curators' Favorite Papers
The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized TrialJason L. Vassy, MD, MPH, SM; Kurt D. Christensen, PhD, MPH; Erica F. Schonman, MPH; Carrie L. Blout, MS, CGC; Jill O. Robinson, MA; Joel B. Krier, MD; Pamela M. Diamond, PhD;
Pharmacogenomics on Nightly News with Lester Holt
The Wednesday, June 28th edition of the Nightly News with Lester Holt featured a short segment on pharmacogenomics.
The piece briefly covered the Mayo Clinic's work in expanding the use of pharmacogenomics in the clinic. Dr. Richard Weinshilboum, co-director of the pharmacogenomics program at the Mayo Clinic, was
AMIA 10x10 Virtual Pharmacogenomics course with Stanford University begins June 26, 2017
The American Medical Informatics Association (AMIA) has partnered with the Biomedical Informatics program at Stanford University to present an online course in pharmacogenomics (PGx) as part of the AMIA 10 x 10 series. The course, Pharmacogenomics, will introduce the field and cover topics relevant to PGx including pharmacology, genomics, genome
The Next Look for PharmGKB
PharmGKB is excited to show you our all-new website design. We’ve been working hard for months to create a new user interface that serves all of PharmGKB’s content in a clear and flexible way.You can see the new design by visiting next.pharmgkb.org.The “next” site